Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables grows, but more slowly than its trailing trend

Q2 FY2026 accounts payables of $1.88M rose 57.0% year over year, behind the +149.2% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 384.4% of revenue in FY2025.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +57.0% toward the trailing-twelve-month pace of +149.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.88M+383.7% QoQ
Last fiscal yearDec 2025
-$346K-10.6% YoY
LTMJun 2026
$721K+149.2% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.0%——
1 year-10.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(346K) USD
Year-over-year change
+10.6%

Accounts Payables vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's LTM Jun 2026 accounts payables of $721K is the smallest of the 5 companies compared; the peer median is $73.47K.
  • Its year-over-year change of +149.2% is the 3rd highest of 5, against a peer median of +58.4%.
  • Accounts payables amounts to 2.1% of revenue for ATNM, versus a peer median of 1.8%.
ATNM Competitors Peer median
Accounts Payables for ATNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANVSAnnovis Bio, Inc.LTM Mar 2026$3.91M +242.7%-55.7%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$2.41M -126.0%——
XLOXilio Therapeutics, Inc.LTM Mar 2026$938K -175.6%-32.1%1.8%
PDSBPDS Biotechnology CorporationLTM Mar 2026$791.06K +301.2%——
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$721K +149.2%—2.1%
Peer median (excluding ATNM) $73.47K+58.4%-43.9%1.8%

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Depreciation & Amortization524K699K790K811K821K
Deferred Income Tax(1.55M)402K000
Stock-Based Compensation1.69M2.8M3.84M5.29M9.19M
Change in Working Capital1.69M38.17M(3.15M)(932K)(704K)
Accounts Receivables00000
Inventory00000
Accounts Payables1.2M4.6M(2.18M)(387K)(346K)
Other Working Capital495K33.57M(972K)(545K)(358K)
Other Non-Cash Items1.55M(402K)000
Operating Cash Flow(20.87M)8.64M(47.34M)(33.07M)(24.58M)
Capital Expenditures(133K)(366K)(153K)(11K)(104K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(133K)(366K)(153K)(11K)(104K)
Debt Repayment(85K)(49K)(4K)(9K)(10K)
Common Stock Issued35.3M23.16M14.87M29.26M0
Common Stock Repurchased0000(207K)
Dividends Paid00000
Other Financing Activities6K0075K0
Financing Cash Flow35.22M23.11M14.87M29.32M(217K)
Effect of Forex Changes00(11K)06K
Net Change in Cash14.22M31.39M(32.63M)(3.76M)(24.9M)
Free Cash Flow(21M)8.28M(47.49M)(33.08M)(24.68M)

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.